InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Explore the full record of transactions filed by ORLOFF JOHN J, Directeur de la Recherche et Développement. Director active across 2 companies, notably ALEXION PHARMACEUTICALS, INC.. Aggregated, 6 filings have been logged. The latest transaction was disclosed on 21 July 2021 — Disposition. Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations6 total
0146,511 shares0
Common Stock, par value $.0001 per share
SEC:0000899866-21-000062·
0146,511 shares0
Common Stock, par value $.0001 per share
SEC:0000899866-21-000062:0·
030,643 shares0
Common Stock, par value $.0001 per share
SEC:0000899866-21-000054·
030,643 shares0
Common Stock, par value $.0001 per share
SEC:0000899866-21-000054:0·
€284,5591,957 shares@ €145.405550.0% of flow
Common Stock, par value $.0001 per share
SEC:0000899866-21-000050:0·
€284,5591,957 shares@ €145.4055100.0% of flow
Common Stock, par value $.0001 per share
SEC:0000899866-21-000050·
6 of 6 declarations
About ORLOFF JOHN J
John J. Orloff is the Executive Vice President of Research & Development at ALEXION PHARMACEUTICALS, INC. In this role, he oversees the company's research and development initiatives, aiming to innovate and improve medical treatments. His scientific expertise is essential for the success of the company's projects.
